Comprehensive Diagnostic Value of P53, p21WAF1 and Proliferating Cell Nuclear Antigen for Lung Cancer

The expression of P53, p21WAF1 and proliferating cell nuclear antigen (PCNA) was detected in 114 samples of lung cancer patients (with 89 cases benign lung tissue as control) and the diagnostic value of these markers was evaluated. The results show the following: ① The positive expression rates of P53, p21WAF1 and PCNA in samples of lung cancer were 47.37%, 75.44% and 80.70%, respectively, which were significantly higher than that in the samples of benign lung diseases ( p ∧0.001). The odds ratios were 39.15, 5.75, and 6.76, respectively. This indicates that the expression of P53, p21WAF1 and PCNA was helpful for the diagnosis of lung cancer. ② For the diagnosis of lung cancer, the positive likelihood ratio of P53 was 21.08, which were significantly higher than that of p21WAF1 (2.16), PCNA (2.11) and of all the combined tests. This shows that P53 expression was the most valuable for diagnosis of lung cancer. ③ For the diagnosis of lung cancer, the negative likelihood ratio of P53/p21WAF1/PCNA parallel test was 0.057 1, which was lower than that of other single and combined tests. This indicates that P53/p21WAF1/PCNA parallel test has high diagnostic value for exclusion of lung cancer.